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Abstract 
Background: New simian–human immunodeficiency chimeric viruses with an HIV-1 env (SHIVenv) are critical for 
studies on HIV pathogenesis, vaccine development, and microbicide testing. Macaques are typically exposed to single 
CCR5-using SHIVenv which in most instances does not reflect the conditions during acute/early HIV infection (AHI) in 
humans. Instead of individual and serial testing new SHIV constructs, a pool of SHIVenv_B derived from 16 acute HIV-1 
infections were constructed using a novel yeast-based SHIV cloning approach and then used to infect macaques.
Results: Even though none of the 16 SHIVenvs contained the recently reported mutations in env genes that could 
significantly enhance their binding affinity to RhCD4, one SHIVenv (i.e. SHIVenv_B3-PRB926) established infection in 
macaques exposed to this pool. AHI SHIVenv_B viruses as well as their HIVenv_B counterparts were analyzed for viral 
protein content, function, and fitness to identify possible difference between SHIVenv_B3-PRB926 and the other 15 
SHIVenvs in the pool. All of the constructs produced SHIV or HIV chimeric with wild type levels of capsid (p27 and 
p24) content, reverse transcriptase (RT) activity, and expressed envelope glycoproteins that could bind to cell recep-
tors CD4/CCR5 and mediate virus entry. HIV-1env_B chimeric viruses were propagated in susceptible cell lines but the 
16 SHIVenv_B variants showed only limited replication in macaque peripheral blood mononuclear cells (PBMCs) and 
174×CEM.CCR5 cell line. AHI chimeric viruses including HIVenv_B3 showed only minor variations in cell entry effi-
ciency and kinetics as well as replicative fitness in human PBMCs. Reduced number of N-link glycosylation sites and 
slightly greater CCR5 affinity/avidity was the only distinguishing feature of env_B3 versus other AHI env’s in the pool, a 
feature also observed in the HIV establishing new infections in humans.
Conclusion: Despite the inability to propagate in primary cells and cell lines, a pool of 16 SHIVenv viruses could 
establish infection but only one virus, SHIVenv_B3 was isolated in the macaque and then shown to repeatedly 
infected macaques. This SHIVenv_B3 virus did not show any distinct phenotypic property from the other 15 SHIVenv 
viruses but did have the fewest N-linked glycosylation sites.
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Background
A major hindrance in drug, vaccine, and microbicide 
development for HIV/AIDS is limited utility of exist-
ing animal models. Human immunodeficiency virus 
type 1 (HIV-1) productively infects only humans and 
chimpanzees. While chimpanzees can be productively 
infected, they are endangered, expensive, do not typi-
cally develop AIDS after HIV-1 infection, and their use 
in research engenders ethical concerns [1]. This narrow 
host range of HIV-1 has compelled researchers to use 
macaque monkeys exposed or infected with SHIVenv, a 
chimera containing HIV-1 env coding regions within a 
simian immunodeficiency virus (SIV) backbone derived 
from rhesus macaques (Macaca mulatta) infections. The 
genomic organization of SIVmac, HIV-1, and SHIV con-
structs are similar but encode for virus with significant 
functional variations. These differences are largely based 
on the accessory proteins, which appear to modulate viral 
replication in a host species-dependent manner impact-
ing virus persistence, spread, and pathogenesis [2–5]. A 
recent study showed that the HIV harboring the SIVmac 
vif gene could establish infection and was pathogenic in 
pigtailed macaques (Macaca nemestrina) depleted for 
CD8+ T cells [6].
SIV strains containing HIV-1 env genes (SHIVenv) 
have been successfully employed to infect macaques 
through intravenous and mucosal routes. Currently, 
most SHIVenv’s are clonal and even following propaga-
tion, do not contain a diverse representative of the HIV-1 
population transmitted from donor to establish infection 
in a recipient with a single HIV-1 clone. Lack of diverse 
SHIVenv populations as innocula for macaque infection 
studies represents a resource gap for the rational devel-
opment of HIV-1 vaccines and testing of microbicides. 
It is also critical to establish new env-based SHIVs for 
studies on pathogenesis and immune responses. How-
ever, the prospect of developing new infectious SHIVenv 
viruses is daunting considering the time consuming clon-
ing procedures, the need for high titer virus propagation 
in extraneous cell lines, and the cost of testing infectivity 
in macaque infectivity using a reiterative SHIV strain-by-
strain approach.
New HIV-1 infections (60–90%) originate from sin-
gle HIV-1 variant or a limited number of transmitted/
founder HIV-1 variants despite exposure to hundreds or 
thousands of HIV-1 clones from the donor partner [7, 
8]. This genetic bottleneck is less pronounced in indi-
viduals engaged in high-risk behaviors (anal-receptive 
intercourse or intravenous drug use) and in patients 
with ongoing sexually transmitted infections [9]. Nota-
bly, acute infection with a “heterogeneous” infecting 
HIV-1 population has been linked to more rapid disease 
progression [10]. As indicated above, most macaque 
models for primary HIV-1 infection involve exposure 
with only a single or highly homogeneous SHIVenv 
virus and do not reflect exposure to the highly heter-
ogenous HIV-1 from donor to recipient. The HIV-1 
clone(s) establishing primary infection in humans may 
have unique phenotypic properties from the inoculating 
HIV-1 population making it more apt for transmission. 
For example, transmitted virus preferentially employs 
CCR5 as co-receptor (R5 tropic) even though CXCR4 
using HIV-1 may be present in the inoculating virus 
population. In the case of external pressure, use of pre-
ventative vaccines and microbicides should block new 
HIV-1 transmission. Prior to human trials, macaque 
models remain crucial for studies on HIV vaccine and 
microbicide testing [11, 12]. However, few CCR5-using 
SHIVenv strains (e.g. SHIVSF162, SHIVCHN19, SHIV1157i-
pd3N4) can maintain stable and prolonged infections 
[13–15]. A recent study used a pool of SHIVenv viruses 
to infect macaques depleted of CD8+ T cells result-
ing identification of two pathogenic SHIVenv strains 
[16]. Other studies suggested that the mutations in Env 
region could enhance macaque CD4-mediated entry and 
viral replication [17, 18]. However, how these mutations 
impact SHIV pathogenesis in macaques has not been 
fully explored.
There were two main objectives for this study and both 
required the initial construction of SHIVs containing the 
transmitted subtype B env genes, derived from the AHIs 
of CHAVI001 and other CHAVI clinical trials. The first 
objective was to identify R5 SHIVenv viruses with high 
transmission efficiency based on exposure of macaques 
to the heterogenous SHIVenv pool. As described herein, 
a single SHIVenv clone established macaque infection 
which prompted comprehensive genotypic and phe-
notypic analyses of why this SHIVenv was transmitted 
versus the other 15 in the pool. These analyses of trans-
mission fitness required a battery of assays to measure 
proper virus assembly, replicative fitness, and the effi-
ciency/kinetics of host cell entry, as well as transmission 
related modification (e.g. glycosylation) in these enve-
lope proteins. The second objective in the companion 
article [19] was to establish a pathogenic R5 SHIV from 
the SHIVenv with the highest transmission efficiency. It 
is important to stress that transmission efficiency and 
pathogenicity is likely related to different virus attributes. 
In past, the serial strain-by-strain cloning then testing in 
macaques has failed to identify a pathogenic R5 SHIVenv 
that provides a macaque model for prolonged HIV-1 
infection in humans. Thus, we have serially passaged the 
highly transmissible SHIVenv to develop a new patho-
genic R5 SHIVenv.
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Methods
Macaque use
Adult rhesus macaques (Macaca mulatta) were housed 
at the New England Primate Research Center and Har-
vard Medical School, a primate animal facility that is 
accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care International. 
Research was conducted in compliance with the Ani-
mal Welfare Act and other US federal statutes and reg-
ulations relating to animals and experiments involving 
animals, and adhered to principles stated in the Guide 
for the Care and Use of Laboratory Animals, National 
Research Council, 1996. All steps were taken to amelio-
rate the welfare and to avoid the suffering of the animals 
in accordance with the “Weatherall report for the use of 
non-human primates” recommendations. Animals were 
housed either socially or in adjoining individual primate 
cages allowing social interactions, under controlled con-
ditions of humidity, temperature and light (12-h light/12-
h dark cycles). Food and water were available ad libitum. 
Animals were fed commercial monkey chow and treats 
by trained personnel. Environmental enrichment con-
sisted of commercial toys. Blood draws were conducted 
under sedation by trained personnel under the supervi-
sion of veterinarian.
Yeast strain and growth conditions
Saccharomyces cerevisiae Hanson (MYA-906), MAT 
alpha ade6 can1 his3 leu2 trp1 URA3, was obtained from 
the American Type Culture Collection (ATCC). Yeast 
was grown at 30  °C in appropriate media depending on 
the cloning step [yeast extract peptone dextrose (YEPD), 
complete (C) minimal media -LEU-URA3, C-LEU, or 
C-LEU/5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrim-
idine carboxylic acid (5-FOA)]. Transformations were 
performed using the lithium acetate (LiAc) method. 
Briefly, the vector DNA and PCR product (~3  μg) were 
added to competent cells at a 1:3 ratio along with 50 µg 
of single stranded salmon sperm carrier DNA (BD Bio-
sciences/Clontech, Palo Alto, CA, USA) and sterile poly-
ethylene glycol (50%)/TE (10 mM Tris–Cl, 1 mM EDTA)/
LiAc (100 mM). Following agitation for 30 min at 30 °C, 
yeast was heat shocked at 42 °C for 15 min and plated on 
C-leu agar plates containing the appropriate selection.
Cell culture
PBMCs were isolated from HIV-1 seronegative donors 
and macaques via Ficoll-Paque density centrifugation and 
cultured in a RPMI-1640 medium with 10% fetal bovine 
serum (FBS). PBMCs were obtained from donors with 
written informed consent in the Cleveland area under 
the UH IRB approval AIDS125 (protocol #01-98-55). 
All informed consent documents were stored in locked, 
secure cabinet and only the person authorized by the 
protocol to obtain informed consent from the participant 
has access to this locked cabinet. The protocol is renewed 
yearly but the year of analyses and collection for this 
study had the expiry date of 06/20/2014. Children were 
not used in this study. The U87.CD4.CXCR4 cell line was 
obtained from the AIDS Research and Reference Rea-
gent Program and grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Cellgro) supplemented with 15% FBS, 
penicillin and streptomycin, puromycin (1  μg/ml) and 
G418 sulfate (1  mg/ml). 293T cells were obtained from 
the American Type Culture Collection and grown in 
DMEM supplemented with 10% FBS and penicillin and 
streptomycin. 174×CEM.CCR5 cells (kindly provided 
by Dr. Nathaniel Landau at SOM, NYU) were grown in 
RPMI-1640 containing 10% FBS, penicillin and strepto-
mycin, 1%HEPES, Puromycin (0.5 μg/ml), G418 (0.3 mg/
ml), and Hygromycin B (200 μg/ml). All cells were grown 
at 37 °C in 5% CO2.
Molecular clones
Twenty acute subtype B envelopes (env, provided by Drs. 
Keele and Hahn, University of Alabama) were cloned 
from the CHAVI acute infection studies [7]. Three 
chronic subtype B envs (i.e. I10, K44, and Q0—isolated 
from patients infected at one to 2  years post infection) 
were cloned from anonymous patient samples under IRB 
approval #07-02-32 at Case Western Reserve University/
University Hospitals of Cleveland IRB. HIV-1 envs were 
cloned using the protocol described in [20]. Approxi-
mately 3  μg of the 2  Kbp env DNA (HXB2 numbering 
6108-8082) from acute infection clones (or from chronic 
infections) were transfected into yeast with linearized 
plasmids, pREC_nfl_SHIVKB9_Δenv/URA3, or pREC_
nfl_HIV_Δenv/URA3. Yeast colonies were selected on 
C-leu plates supplemented with FOA but lacking leucine. 
Approximately 95% of FOA-resistant yeast colonies har-
bored pREC_nfl_SHIVKB9 or pREC_nfl_HIV with the 
patient env. A crude yeast lysate was then used to trans-
form bacteria and to amplify these ampicillin-resistant 
DNA plasmids for purification as described [20]. It is 
important to note that, for the chronic patient samples, 
the env PCR product contained the amplified HIV-1 
population in that patient sample and as such, >100 yeast 
colonies were removed from C-leu/FOA plates for bulk 
plasmid purification and for eventual reconstitution of 
HIV-1 env quasispecies. In contrast, only a single acute 
env clone was subcloned into pREC_nfl_SHIVKB9_ Δenv/
URA3 or pREC_nfl_HIV_ Δenv/URA3; this represents 
the limited genetic diversity in the acute sample. It is also 
important to stress that SHIVKB9 is a SIVmac239 virus 
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containing only a portion of HIV-1 env gene, i.e. from the 
1st exon of Tat to the end on the 2nd exon of Tat (HXB2 
numbering nt5823-nt8676). The URA3 gene replaces in 
the pREC_nfl_HIV_Δenv/URA3 only replaces a region 
still flanked by KB9 sequence (HXB2 numbering nt5996-
nt8638). In contrast, the SHIVenv vectors and virus con-
tain the AHI subtype B env coding sequence within the 
KB9 tat1/gp120/tat2 coding sequence (HXB2 numbering 
6108-8082).
Production of SHIVenv, and HIVenv chimeric viruses
The vectors, pREC_nfl_SHIVenv_X (i.e. with patient X 
env) were then co-transfected into 293T cells with the 
complementing vector, pREC_cplt_R/U5/gag/pol [21], 
using Effectene Transfection Reagent (QIAGEN). As pre-
viously described [20], these co-transfected 293T cells 
produced virus particles harboring either two comple-
ment RNA genomes (SHIV_cplt_R/U5/gag/Δpol RNA), 
two near full length SHIV genomes (nfl_SHIVenv_X 
RNA), or both. Only the latter can propagate in suscep-
tible cells or animals. Supernatant containing these three 
forms of viruses was harvested from the transfected 
293T cells at 48  h, monitored for RT activity, and used 
for virus propagations in various susceptible cell lines 
(U87.CD.CCR5, 174×CEM.CCR5, human and macaque 
PBMCs). Similarly, the HIVenv viruses were produced 
through co-transfection of 293T cells with pREC_nfl_
HIV_env_X and the complementary vector, pCMV_cplt 
[20]. The supernatants from transfected 293T were added 
to U87.CD4.CCR5 cells to produce infectious virus as 
described [20]. Virus production was monitored in the 
culture fluids using a reverse transcriptase (RT) assay as 
described [22]. SHIV p27 capsid levels in the superna-
tants of transfected 293T cells or infected cell lines was 
also measured using the RETRO-TEK SIV p27 Antigen 
ELISA assay (ZeptoMetrix Corporation) according to the 
manufacturer protocol.
Virtual and actual TCID50 determinations
Since the SHIVenv viruses showed limited replication in 
primary cells and cell lines, these virus titers were esti-
mated from RT activity using “Virtual TCID50 assay” as 
previously described [22]. Briefly, serial dilutions (1:4) of 
each HIV-1env and SHIVenv chimeric virus were per-
formed in quadruplicate and then used (1) to infect U87.
CD4.CCR5 cells (only with HIV-1env) or (2) to deter-
mine the RT activity in each dilution. There was nearly a 
perfect correlation (r > 0.95, p < 0.001; Pearson product 
moment correlation) between HIV-1env infectious titers 
(as determined by an actual TCID50 assay) and the virtual 
titers measured by RT activity. Thus, the SHIVenv titers 
were estimated from the RT activity in the serial dilutions 
of the virus-containing 293T supernatants.
Veritrop assay
The function of the HIV-1 env insert within the HIV-1 
or SHIVKB9 backbone was analyzed using a cell-to-cell 
fusion assay, Veritrop as described [23]. Approximately 
5  ×  105 U87.CD4.CCR5 cells were transfected with 
pDM128fLuc using the FuGENE 6 Transfection Reagent 
(Roche) according to the protocol provided by manufac-
turer. Concurrently, 293T cells (5–6 × 104 cells per well) 
were transfected with pREC_nfl_SHIVenvX vector. After 
24  h (on day 2), the pREC_nfl_SHIVenv_X transfected 
293T cells were layered on top of the pDM128fLuc-trans-
fected U87.CD4.CCR5 cells (5–6 × 104 cells per well) in 
a 24 well plate. At 48  h, cells were harvested and lysed 
with 100 μl of Glo Lysis Buffer and combined with 50 μl 
of Bright Glo (Promega Biotech), then read with Victor3 
V (Perkin Elmer) for luciferase activity.
Affinofile assay
Affinofile cells were employed to examine CD4 and 
CCR5 affinity/avidity during virus entry as previously 
described [24, 25]. Affinofile cells were plated at a den-
sity of 10,000 cells per well in a 96-well plate and then 
induced to express high to low levels of CD4 with mino-
cycline (5–0  ng/ml, twofold dilutions over six separate 
dilutions) [25] and high and low CCR5 expression with 
ponasterone A (4 and 0.125  μM) as described [24, 25]. 
Cells were induced for 24 h prior to infection with HIV-1 
pseudotyped with the various AHI env genes [24, 25] for 
48  h, washed with PBS, and lysed with Glo lysis buffer 
(Promega, Inc.). Maximal infection was considered lucif-
erase activity generated by infection at the highest CD4 
and highest CCR5 concentration. CCR5 and CXCR4 
expression levels per cell was measured at 24 h (prior to 
infection) by flow cytometry as described [24, 25].
HIV‑1 competitions for replicative fitness analyses
Dual virus infections were performed in PHA-activated, 
IL2-treated peripheral blood mononuclear cells of HIV-
negative donors as described [26]. Each HIV-1env chi-
meric virus derived from an AHI was competed against 
three competitor viruses, i.e. HIV-1env chimeric viruses 
derived from chronic subtype B infections (Q0, I10, and 
K44). Dual infections involved both AHI and reference 
viruses added to PBMCs at 0.005 multiplicity of infec-
tion (MOI). Overall virus production was monitored by 
RT activity. Relative virus production and fitness was 
analyzed by the classical heteroduplex tracking assay 
described in [26, 27] and by using an amplicon-based 454 
pyrosequencing approach (described below).
454 pyrosequencing
Genomic DNA from dually infected cells was isolated 
using the QIAamp 96 DNA Blood Kit. PCR primers were 
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designed for Roche GS Flx System and modeled after the 
E110-E125 primer pairs (sequence: 5′-CTGTTAAATGG 
CAGTCTAGCAGAA, and 5′-CAATTTCTGGGTCCC 
CTCCTGAGG) where the E110 primer (i.e. Roche GS 
FLX A and B primers) contained a five base-pair barcode 
(GCCTCCCTCGCGCCAXXXXX) and the E125 primer 
represented the Roche GS FLX B primer. The 250 E110 
primers were designed with distinct barcodes and to 
be paired with E125. Using two HIV-1 DNA templates, 
PCR with each primer pair resulted in equal amplifica-
tion efficiency and the same size DNA product (357 bp). 
One DNA sample from a single competition was PCR 
amplified with one designated primer pair. Please note, 
in order to eliminate the possible PCR-induced recom-
binants, we used Phusion High-Fidelity DNA Polymerase 
(NEB) which can rapidly complete the DNA extension 
(15–30 s per Kb) and longer extension time (2 min). PCR 
products were purified using the QIAquick 96 PCR Puri-
fication Kit and quantified using Quant-iT PicoGreen 
dsDNA Assay Kit (Invitrogen), and then equalized to a 
concentration of 10 ng/μl. Samples were pooled into two 
tubes to prevent redundancy of barcoded primer used for 
the amplification of samples. We used GS emPCR Kit II 
(Roche) to obtain reads starting from Primer A. Ampli-
cons were added to the emulsion at one copy per bead. 
EmPCR was done according to the Roche EmPCR man-
ual, and Amplicon sequencing was performed according 
to the Roche Amplicon sequencing manual. Sequences 
were processed and collected using Roche GS FLX Sys-
tem software. Sequences were extracted according to 
barcode by the Java script Extraction (written by John 
Archer) and sorted by barcode into a folder containing 
to different files (raw sequence, aligned sequence, and 
predicted amino acid sequence) related to specific dual 
virus competitions. The extracted sequences were then 
analyzed using the Competition Table java script, which 
aligns and counts specific sequences derived from 454 
analyses (and with a specific barcode) using the known 
reference sequences. Additionally, phylogenetic trees 
were generated for ~20% of the competitions to verify 
the results from the Competition Table java script. It is 
important to stress that any errors generated by 454, as 
we have previously described [28], do not impact the 
determination of replicative fitness. Competition Table 
java script aligns to one of two HIV-1 sequences in the 
competition (based on the input sequences of these AHI 
env clones) such that any single and multiple point muta-
tions within a viral quasispecies or generated by PCR/454 
error still aligns to one of two diverse HIV-1 (found in 
the competition). Production of each HIV-1 isolate (as 
determined by sequence count) in a dual infection (f0) 
was divided by the initial proportion in the inoculum 
(i0) to determine the relative fitness (W =  f0/i0). Fitness 
difference (WD) is the ratio of the relative fitness values 
of each HIV-1 isolate in the competition (WD = wM/wL) 
[26, 27]. Finally, the relative fitness values in a competi-
tion derived by 454 sequence analyses showed less than 
10% variance with those derived by HTA analyses (data 
not shown).
Results
Construction of yeast‑based cloning vectors for producing 
SHIVenv viruses
We previously constructed pREC_nfl_HIV and pCMV_
cplt vectors for yeast-based cloning of diverse HIV-1 
strains [20]. As described in Additional file 1: Figure S1, 
we developed a similar method for SIV and SHIV clon-
ing. The 5′ half of HIV genome in pREC_nfl_HIV vector 
was first replaced with URA3 then substituted with the 5′ 
half of the SHIVKB9 genome. The 3′ half of SHIVKB9 was 
introduced using the same procedure to form the vector 
of pREC_nfl_SHIVKB9; this vector contains the near full 
length of SHIVKB9 genome and lacks the 5′ repeat (R) and 
unique (U5) regions. The complementing vector, pREC_
SHIVKB9_cplt_R/U5/gag was constructed by swapping 
the 5′LTR/gag sequence of HIV-1 with that of SHIVKB9 as 
described (Additional file 1: Figure S1).
To test this SHIVKB9 vector system, pREC_nfl_
SHIVKB9 and the complementing vector, pREC_cplt_R/
U5/gag, were co-transfected into 293T cells to pro-
duce SHIVKB9 virus, which was then used to infect 
174×CEM.CCR5 cells, a human B&T cell hybrid line. 
The parent virus, SHIVKB9, produced by 293T co-
transfections, could be propagated in 174×CEM.CCR5 
cells as previously reported [29] but virus production 
(12  days post-infection) was delayed when compared 
to that of HIV-1NL4-3 (3  days post-infection) (Addi-
tional file 2: Figure S2 A). This delay in virus outgrowth 
is consistent with previous studies of SHIVKB9 virus 
propagation [30]. SHIVKB9 could infect and replicate in 
U87.CD4.CCR5 cell cultures but only after initial prop-
agation on 174×CEM.CCR5 cells whereas SHIVKB9 
derived from the transfected 293T supernatants did 
not expand in U87.CD4.CCR5 cells (Additional file  2: 
Figure S2 B).
To produce the SHIVenv chimeric virus, we first con-
structed pREC_nfl_SHIVKB9_Δenv/URA3 vector in 
which SHIVKB9 env was replaced with the URA3 gene 
of yeast. It is also important to stress that SHIVKB9 is 
a SIVmac239 virus containing only a portion of the 
HIV-1 env89.6 gene, i.e. from the 1st exon of tat to the 
end of the 2nd exon of tat (HXB2 numbering nt5823-
nt8676). The URA3 gene replaced only the HIV-1 
sequences in KB9 (HXB2 numbering nt5996-nt8638) to 
generate the pREC_nfl_SHIVKB9_Δenv/URA3 cloning 
vector (Fig. 1).
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SHIVenv chimeric virus production
Twenty PCR-amplified subtype B env clones (B1 to B20; 
Fig. 1a), isolated from acute HIV infections, were cloned 
into the pREC_nfl_SHIVKB9_Δenv/URA3 vector via yeast 
recombination/gap repair [20] (Fig.  1b). The pREC_nfl_
SHIVenv_B1-to-B20 vectors were then co-transfected 
with the complementary vector pREC_cplt_R/U5/gag 
into 293T cells to produce SHIVKB9env_B1 to SHIV 
KB9env_B20 viruses (designated as SHIVenv_BX for sim-
plicity thereafter), which were then tested for infectivity 
in different cell lines (i.e. U87.CD4.CCR5 and 174×CEM.
CCR5), human and macaque PBMCs. Only transient 
replication over 5–7  days was observed with the 20 
SHIVenv_B1 to _B20 viruses in the various cell lines, 
Fig. 1 Production of pREC_nfl_SHIVenv containing the gp120 coding region derived from acute HIV-1 infections. a Construction of pREC_nfl_
SHIVKB9_envB vector/URA3. The URA3 gene and the corresponding AHI env B genes only replace a region flanked by KB9 sequence (HXB2 number-
ing nt5996-nt8638). SHIVKB9 is a SIVmac239 virus containing only a portion of the HIV-1 env89.6 gene, i.e. from the 1st exon of tat to the end on the 
2nd exon of tat (HXB2 numbering nt5823-nt8676, shadowed in yellow). b 20 acute HIV-1 subtype B envelope (Env) and three chronic HIV-1 Envs (i.e. 
I10, K44, and Q0) were cloned into pREC_nfl_SHIVKB9Δenv/URA3 (or pREC_nfl_HIVΔenv/URA3) by homologous yeast recombination/gap repair to 
produce the pREC_nfl_SHIVKB9_envB1-20 and pREC_nfl_HIVenv_B1-20 vectors
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macaque, and human primary cells. The SHIV with the 
AHI envs could not be propagated or expanded, while the 
parent SHIVKB9 virus was efficiently propagated in both 
macaque PBMCs and 174×CEM.CCR5 cells (Fig. 2a, c). 
The same cloning and virus production procedure were 
employed to produce the HIV-1env_B1 to _B20 chimeric 
viruses (the counterpart to the SHIVenv_B1 to _B20). In 
contrast to the SHIVenv viruses, all of the HIV-1env_BX 
chimeric viruses containing the subtype B AHI envelope 
in an NL4-3 backbone were infectious and were passaged 
through a susceptible cell line (i.e. U87.CD4.CCR5) and 
human PBMCs, but not macaque PBMCs (Fig. 2b).
Testing of the function of HIV‑1 envelope proteins 
in SHIVKB9 backbone
Inability of the SHIVenv_B1 to _B20 chimeric viruses 
to propagate in cell lines and primary cells could be 
related to incompatibility between the HIV-1 insert 
and the SHIVKB9 backbone. It is important to note that 
SHIVKB9 backbone contains an HIV-1 KB9 env gene that 
extends from the beginning of tat1 to the end of tat2/
rev2. All of our env_B cassettes were placed within the 
KB9 sequence (see “Methods” section). The function of 
the HIV-1 envelope protein in the context of SHIVKB9 
backbone was tested using the Veritrop Assay, a cell-to-
cell fusion assay. 293T cells were transfected with the 
pREC_nfl_SHIVKB9env_B vectors and then layered over 
U87.CD4.CCR5 cells transfected with vector expressing 
firefly luciferase under the control of both HIV-1 Tat and 
Rev (Fig. 3a). Unlike other cell-to-cell fusion systems, our 
pREC_nfl vectors express all of the viral proteins, in the 
correct stoichiometry, and with the ability to form virus 
particles [20]. However, in the absence of the comple-
menting vector, these virus particles are non-infectious. 
Fig. 2 Chimeric viruses SHIVenv_B and HIVenv_B propagation in different PBMCs and cell lines. U87.CD4.CCR5, 174×CEM.CCR5, human PBMCs 
or macaque PBMCs were exposed to SHIVenv_B3, _B11, and _B20 (a), or HIVenv_B3, _B11, and _B20 (b), or SHIVenv_KB9 (c) chimeric viruses. Virus 
production was measure by RT activity in the supernatant over 17 days
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We recently discovered that our cell fusion assays (Veri-
trop) is approximately 100-fold more efficient than cell 
fusion system mediated by just an Env expression vector 
(R. Gibson, E. J. Arts, D. McDonald, et al. manuscript in 
preparation).
Using our Veritrop assays, the majority of Env glyco-
proteins derived from pREC_nfl_SHIVKB9env_B were 
capable of binding to the CD4 and CCR5 receptors and 
mediating cell fusion (Fig.  3b). Only 3/20 SHIVenv_B 
vectors (i.e. B1, B2, and B11) did not mediate sufficient 
cell-to-cell fusion to justify inclusion in the SHIVenv_B 
pools for future macaque infection studies (see below). 
Interestingly, dysfunction did not appear to be related 
to the AHI sequence since (1) all the B clones were func-
tional in the HIV-1NL4-3 backbone and (2) the AHI env 
sequences were in the correct reading frame with the 
flanking KB9 env sequences. This data suggest that the 
function of these Env glycoproteins may be impacted 
Fig. 3 Veritrop assay detecting the function of the HIV-1 envelope proteins in the context of SHIVKB9 backbone. A schematic of the Veritrop cell-
to-cell fusion assay is shown in (a). The target cell, U87.CD4.CCR5 was transfected with pDM128fLuc, a vector where expression of firefly luciferase 
gene is dependent on both HIV-1 Rev and Tat produced by the effector cell [34]. The effector cell is transfected with pREC_nfl_SHIVKB9env_B vectors, 
which express entire SHIV proteome and produce virus particles that lack the proper SHIV genomic RNA for de novo replication [20]. Levels of cell 
fusion (via relative light units from Luciferase activity) are shown for the effector cells transfected with pREC_nfl_SHIV KB9env_B vectors (b)
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by poor complementation in the KB9 backbone. We did 
confirm gp120 expression by Western blot for a subset of 
the pREC_nfl_SHIVKB9env_B and pREC_nfl_HIV-1NL4-3 
env_B expression vectors transfected into 293T cells 
(data not shown).
Testing of the expression level of P27 and reverse 
transcriptase in SHIVenv_B chimeric viruses
The majority of the SHIVKB9env_B constructs could 
express functional HIV-1 envelope glycoproteins and 
yet, these viruses showed limited replication in different 
cell lines or macaque PBMCs. However, it is also impor-
tant to note that SHIVenv and some SIV strains com-
monly show poor replication efficiency in cell culture 
despite the ability to infect macaques [13, 30, 31]. For a 
crude assessment of the virus particles, expression of 
p27 capsid levels and reverse transcriptase activity was 
measured in the SHIVenv_B derived from supernatants 
of transfected 293T cells. SHIVenv_B1, _B3, _B11, _B14, 
_B17, and _B20 (except SHIVenvB4) had similar or higher 
levels of p27 capsid protein and RT activity than SHIVKB9 
(Fig. 4a). The ratio of p27 capsid to RT activity was simi-
lar for all of these SHIVenv_B viruses (Fig. 4a–c).
SHIVenv infection in rhesus macaques
Following the assessment of p27 capsid levels, RT activ-
ity, and envelope glycoprotein function, we combined 
~100  IU of 16 SHIVenvB (i.e. B3, B5-B10, B12-B20, 
~1600  IU in total). Two animals (m328-08) were then 
intravenously injected with the SHIVenv_B pool (Fig. 5a). 
One macaque (i.e. 328-08) was infected showing peak 
viremia of 107 copies/ml at 3  weeks post exposure. The 
infected 328-08 macaque supported sustained viral rep-
lication over a period of 3 months even though the viral 
level decreased to 103 copies/ml by day 40 post-infection.
Plasma samples were collected from m328-08 at vari-
ous time points and RT-PCR amplified for the SHIV env 
DNA. We performed clonal sequencing and 454 pyrose-
quencing of the C2-V3 region at days 14, 19 and 26 of 
m328-08. Both Sanger sequencing of at least 15 clones 
from each time point (Fig.  6a) and 454 pyrosequenc-
ing at read depth of ~1000 sequences/sample revealed 
that only a single clone (i.e. B3-PRB926) in the pool of 
16 SHIVenv_B chimeric viruses established infection 
in m328-08. The average read length of ~500 nt for 454 
pyrosequencing was trimmed to 300  nt, aligned using 
Beast, and presented on the phylogenetic tree in Fig. 6b. 
Although all sequences in all time points aligned with a 
SHIVenv_B3, the virus at d19 in m328-08 had two dis-
tinct B3 clades at nearly equal proportions. By day 26, 
the more divergent B3 clade could be identified. The sec-
ond clade could be related to a PCR and/or sequencing 
error but this appears unlikely considering that at least 
5–10 nt substitutions separate the two clades. The most 
obvious possibility is a recombination between B3 and 
one or more of other 15 SHIVenv_B viruses in the pool. 
However, preliminary analyses using Frag-Dist [32] could 
not identify simple breakpoints and regions of homology 
between B3 and other 15 env_B clones. More thorough 
analyses using program such SplitTree [33] are ongoing.
Based the preferential infection of SHIVenv_B3 over 
the other 15 SHIVenv_B viruses, we exposed another 
three macaques to this virus pool but again failed to 
establish infection. However, three macaques were 
infected by an inoculum containing just SHIVenv_B3 
virus (100 IUs) (Fig. 5b). These three macaques infected 
with SHIVenv_B3 virus reached peak viremia (104.4–7.1 
copies/ml) at day 21 or day 28 and the viral level still 
maintained around 103 copies/ml by day 140. It is 
Fig. 4 Expression of p27 capsid and reverse transcriptase of the 
SHIVenv_B in the transfection supernatant from 293T cells. SIV p27 
was monitored by antigen capture assay in the supernatant of 293T 
cells transfected with pREC_SHIVKB9env_B (B1, B3, B4, B11, B14, B17 
and B20) (a). Reverse transcriptase activity was also measured using 
serial dilutions of the supernatant from the same transfected cells. 
RT activity is report as virtual TCID50 as previously described (b) [22]. 
The correlation of p27 and virtual TCID50 of each SHIVenv_B virus was 
plotted (c)
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important to note that SHIVenv_B3 virus had similar p27 
capsid levels, RT activity, and Env function as the other 
15 SHIVenv_B viruses. None of the SHIVenv_B viruses 
derived from AHI could propagate in cell lines or pri-
mary PBMCs.
Sensitivity to entry inhibitors, kinetics and efficiencies 
of host cell entry
Since SHIVenv viruses cannot maintain virus replica-
tion in culture, we cloned the identical env cassettes into 
HIV-1 vectors for subsequent studies characterizing the 
“transmission” phenotype of the Env_B3 versus other 
Env’s derived from AHI. We used the Affinofile sys-
tem to measure the efficiency of HIV-1 entry into host 
cells expressing a range of physiological CCR5 and CD4 
receptor concentrations on the cell surface. As previ-
ously described, greatest dynamic range in HIV-1 entry 
was observed with low and high levels of CCR5 (~1400 
and 16,000 per cell) with varying levels of CD4 receptor 
(2500–125,000 copies/cell) [24, 25] (Fig. 7). Twelve wells 
with these CD4/CCR5 levels on 293T cells were exposed 
to each of the 20 HIV-1env_B viruses and 38 other HIV-
1env chimeric viruses from the NYU/Aaron Diamond 
AHI cohort. Virus entry was monitored by Rev/Tat 
induction of the luciferase expression (see “Methods”). 
As described in Fig. 7b–e, we could not distinguish sig-
nificant differences between any of the 20 HIV-1env chi-
meric viruses in terms of utilizing CD4 and CCR5 for 
host cell entry. The HIV-1env_B3 virus appears slightly 
more efficient at virus entry with high CCR5 levels across 
a range of CD4 when compared to other AHI chimeric 
env viruses. Nonetheless, these differences between B3 
versus and other HIV-1env_B chimeric viruses were not 
significant based on the triplicate analyses. This slight 
advantage in entry efficiency by the B3 virus was not 
observed at low CCR5 levels.
Fig. 5 SHIV replication in macaques exposed to a pool of 16 SHIVenv_B viruses or just SHIVenv_B3. a The SHIVenv_B pool harboring 16 chimeric 
viruses were intravenously injected into two macaques of Indian origin. Infection of the two macaques was monitored by collecting plasma sam-
ples for 62 days and measuring viral RNA levels by quantitative real time RT-PCR for SIV Gag (Duke Human Vaccine Institute). Results are only shown 
for animal m328-08 in which SHIVenv infection was established. b The SHIVenv_B3 was used to infect three other rhesus macaques of Indian origin. 
Viral RNA was monitored for 140 days
(See figure on next page.) 
Fig. 6 Sequence analyses from plasma of the infected macaques. HIV RNA was extracted from plasma collected from the m328-08 and then 
subjected to RT-PCR amplification, TOPO cloning, and sequence analyses of 15–19 clones from days 14, 19, and 26 post inoculation. A 480 nt gp120 
coding region (C2-V3) of the m328-08 clones were aligned with all the SHIVenv_B clones within the inoculating pool using CluxtalX. Neighbor 
joining trees were constructed using FigTree and presented in (a). Only a single SHIVenv_B3 clone established and maintained infection in macaque 
328-08. The RT-PCR amplified HIV-1 gp120 product derived from ~10,000 RNA copies at day 19 was subjected to 454 pyrosequencing. The C2-V3 
sequences from day 19, the 16 SHIVenv_B sequences from the inoculating pool, and a set of subtype B reference sequences were aligned using 
Bayesian algorithm (Beast) [73] and trees were constructed using a maximum likelihood method. The tree presented in b was drawn with FigTree 
v1.4 (http://tree.bio.ed.ac.uk/software/figtree)
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Sensitivity to entry inhibitors is another method to 
detect phenotypic differences between HIV-1env chi-
meric viruses. Each HIV-1env_B virus was tested for 
inhibition by enfivuritide (ENF; a fusion inhibitor), 
TAK779, and maraviroc (MVC; CCR5 antagonists). 
Inhibitory concentrations for 50% inhibition (IC50) were 
plotted for each virus in Fig. 8a. Overall, all HIV-1env_B 
viruses including HIV-1env_B3 had similar IC50 values 
to ENF, TAK779, and MVC. HIV-1env_B3 may be slight 
more sensitive to MVC inhibition but again this virus was 
not an outlier when compared to range in MVC IC50 val-
ues with HIV-1env chimeric viruses derived from NYU/
ADARC AHI samples.
Finally, entry kinetics was measured with the HIV-
1env_B samples by performing time-of-drug inhibition 
experiments. Various entry inhibitors (soluble CD4, 
Fig. 7 Using the Affinofile system to measure entry efficiency of the HIVenv_B chimeric viruses. a The 293-Affinofile cells were treated with 
ponasterone A (4 and 0.125 ng/ml) to obtain high (~15,830 copies/cell) and low CCR5 surface expression (~1365 copies/cell) and with increasing 
concentrations of minocycline to obtain range of CD4 surface expression (1800–125,000 copies/cell). 293T cells with different CD4/CCR5 levels 
were exposed to each of the Env pseudotyped viruses [25] using the Env expression plasmids derived the CHAVI AHI [7] (b, c) and the NYU/Aaron 
Diamond AHI cohort [25] (d, e). Virus production was monitored by luciferase expression from the LucAM transgene [25]. An average maximal 
infection was calculated from the relative light units (RLUs) produced from infection of 293T with the highest CD4 and CCR5 surface expression. All 
other levels of infectivity are plotted as a percentage of the RLU obtained relative to RLU with maximal CD4 and CCR5 expression. b, c Indicate levels 
of infectivity at high CCR5 over a range of CD4 and d, e, low CCR5 over a range of CD4. The level of infectivity was measured and presented for all 
HIV-1env clones derived from AHI (b), only those HIV-1env clones from CHAVI AHI patients which were also used to construct the SHIVenv pool 
(c). In all four graphs, the level of infectivity with the HIV-1env B3 clone (i.e. the SHIVenv_B clone establishing infection in the macaque) is indicated 
with purple line. The dark blue and light blue lines are the levels of infectivity using the AHI HIV-1env clones from CHAVI and the NYU/Aaron Diamond 
cohort, respectively
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MVC/TAK779, or ENF) block different steps but not the 
entire host cell entry process and as such, we examined 
the timing of complete virus entry using a nucleoside RT 
inhibitor (lamivudine) to block the subsequent step in the 
virus life cycle, i.e. reverse transcription. In addition, the 
RT coding region is isogenic in this chimeric virus and 
any increase or decrease in the time window of 3TC inhi-
bition likely reflects differences in the preceding entry 
step and not in the reverse transcription step. When 
comparing the T1/2 for 3TC among the HIV-1env chi-
meric viruses, there was ~2 h range in the time required 
for entry which is consistent with previous studies [25, 
34]. The predicted time for HIV-1env_B3 entry into host 
cells falls within the time range for entry of the other 
HIV-1env_B chimeric viruses (Fig.  8b). Based on entry 
efficiency/receptor utilization, sensitivity to entry inhibi-
tors, and entry kinetics, there was no statistical evidence 
to suggest that Env_B3 glycoprotein was better than the 
other Env_B glycoprotein in the HIV-1 backbone. How-
ever, the trend for increased Env_B3 function in all three 
activities might suggest a collective fitness advantage of 
SHIVenv_B3 over the other SHIVenv_B’s in the inoculat-
ing pool.
Replicative fitness of the HIV‑1env chimeric viruses
Receptor binding, entry efficiency and kinetics are only 
one set of factors in determining replicative fitness. How-
ever, with Env chimeric viruses and isogenic backbone, 
we have reported that replicative fitness maps to the env 
gene and is typically dominated by entry efficiency [27, 
35, 36]. To investigate the fitness differences among these 
20 AHI envelope clones, HIV-1env chimeric viruses were 
competed against three subtype B reference viruses (i.e. 
HIVenv_I10, HIVenv_K44, and HIVenv_Q0) in HIV-neg-
ative PBMCs (Fig.  9a). Following 10  days of dual infec-
tion, a segment of the HIV-1 env gene was PCR amplified 
with primers containing barcodes for 454 amplicon 
pyrosequencing. Each barcoded “bin” of sequences were 
aligned to the two viral sequences in the competition 
and counted to determine the relative replicative fitness 
values in each dual infection (Fig.  9a). Details of this 
method and comparisons to other classical approaches 
to measure dual virus production were described in 
[26, 27]). Based on these fitness analyses, B16, B4 and 
B20 in HIV-1NL4-3 backbones had highest replicative fit-
ness when competed against the three subtype B refer-



































































































Fig. 8 Sensitivity to entry inhibitors and entry kinetics. a Each HIV-1env_B virus (CHAVI acute, NYU acute, and two chronic HIV-1 strains as control) 
was tested for inhibition by enfuvirtide, TAK779, and maraviroc. Inhibitory concentration for 50% inhibition (IC50) was plotted for AHI HIV-1env 
viruses in a. The IC50 values of HIV-1env_B3 are shown with purple symbols. b Entry kinetics was measured with the HIV-1env_B samples by perform-
ing time-of-drug inhibition experiments with the RT inhibitor, 3TC
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was outcompeted by all three reference strains and was 
in the lower range of replicative fitness when compared 
to the other HIV-1env_B chimeric viruses. In fact, HIV-
1env_B3 ranked 14th in relative replicative fitness out of 
the 19 HIV-1env_B viruses (B8 failed for the detection) 
and 11th out of the 16 chimeric viruses encompassing 
the SHIVenv_B pool used to infect macaques. Again the 
fitness difference in PBMCs did not provide evidence 
of significantly different Env_B3 phenotype compared 
to the other AHI Env_B viruses in the pool that did not 
establish macaque infection.
Comparison of glycosylation and V3 net charge in the AHI 
Env clones
Previous studies have reported that transmitted 
HIV-1 clones in new recipients have fewer N-linked 
Fig. 9 The fitness difference of AHI HIV-1env chimeric virus relative to the control HIV-1env chimeric virus derived from chronic infection. As 
described in the schematic (a), HIV-1env_B chimeric viruses were competed against three reference viruses (i.e. HIVenv_I10, HIVenv_K44, and 
HIVenv_Q0) in HIV-negative PBMCs as described in the “Methods” section. a is also schematic describing the PCR and 454 pyrosequencing methods 
used to detect and quantify dual infection (see “Methods” section for more detail). The percent replication relative to HIVenv_I10, HIVenv_K44, and 
HIVenv_Q0 is shown in b. Total relative fitness (the addition of all relative fitness values) is presented in c to provide a rank order for relative fitness 
for the 19 HIVenv viruses tested
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glycosylation sites in the HIV-1 Env glycoprotein. Two 
inter-related hypotheses have emerged: (1) a more com-
pact Env with reduced glycosylation may have higher 
replicative capacity and (2) altered and increased glyco-
sylation on HIV is necessary for escape from humoral 
response. In the absence of humoral response during 
initial acute/early infection, a more fit, less glycosylated 
form of HIV-1 may be transmitted. However, we have not 
observed a correlation between the number and position 
of N-linked glycosylation sites in Env with the replica-
tive fitness of the chimeric HIV-1env viruses in primary 
human T cells, macrophages, or dendritic cells [37]. We 
compared the putative N linked glycosylation sites in 
our AHI Env glycoproteins and in the consensus subtype 
sequences. Aside from Env_B19, Env_B3 has the fewest 
putative (Fig. 10a) and conserved (b) N linked glycosyla-
tion sites. The reduction in N linked sites in Env_B3 was 
observed the V1/V2 and V4/V5 variable loops (Fig. 10c, 
d).
The net charge of the V3 loop and Position-Specific 
Scoring Matrix (PSSM) is scaling system to predict 
relative co-receptor usage, i.e. a low net charge and more 
negative PSSM score relates to CCR5 usage for HIV-1 
entry into host cells. The Env_B3 has one of lowest net 
positive charges (Fig.  10e) and lowest negative PSSM 
scores (Fig. 10f ) of all the other CCR5-using AHI Env’s.
Discussion
Simian immunodeficiency viruses (SIV) or chimeras 
encoding the HIV-1 envelope (SHIVenv) are the most 
widely used in animal models of human HIV-1 infec-
tion [38–41] but both have their shortcomings for HIV-1 
prevention, vaccine, and pathogenesis studies. SIVmac 
was initially isolated from a macaque monkey in captiv-
ity who developed an AIDS-like disease [38, 42] which 
prompted isolation of SIVmac239, a clone that causes dis-
ease progression in these monkeys [43, 44]. Subsequently, 
species-specific SIVs were isolated from various monkeys 
such as sooty mangabeys (SIVsmm) [45], African green 
monkeys (SIVagm) [46, 47] and mandrills (SIVmnd) [48]. 
These SIVs establish asymptomatic, chronic infections 
with slow or no progression to disease in their natural 
Fig. 10 Characterization of envB3 and other env clones in SHIVenv_B pool. Comparison of putative N-linked glycosylation sites in the HIVenv_B 
sequences (a), in conserved region (b), in V1/V2 region (c), and in V4/V5 region (d). Net positive charge (e) and PSSM score (f) were also calculated 
for the HIVenv_B sequences
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hosts. It has been suggested that SIVmac emerged via 
a cross-species infection of the rhesus macaque with 
SIVsmm naturally found in sooty mangabeys [45, 49]. 
SIVmac is similar to HIV-1 in genomic organization 
and somewhat similar in pathogenicity, e.g. depletion of 
CD4+ T cells in the gut early in disease [50]. Both viruses 
can use CCR5 as a coreceptor and target CD4+ cells 
such as T-lymphocytes and macrophages, resulting in 
the complete loss of these cells but the disease course in 
macaques infected with SIVmac is short relative to that 
of HIV-1 infections (1–3 years versus 6–10 years). Infec-
tion of macaque monkeys with SIVmac is widely used as 
a model for HIV/AIDS to study disease progression and 
virus transmission but has significant limitation for pre-
vention and vaccine studies.
With the results of the RV144 Thailand trial [51–53] 
and the identification of broadly neutralizing antibod-
ies, there is a renewed interest in humoral-based HIV 
vaccines as well as treatment with anti-HIV antibodies 
for both prevention and therapeutic use. Human trials 
with new vaccines or prevention strategies are typically 
preceded by safety and efficacy tests in macaque models. 
However, lack of diverse SHIVenv strains as challenge 
virus in macaques limits these vaccine and microbicide 
tests. Several vaccines tested with monovalent challenge 
SHIV did show complete efficacy in macaques but were 
less than optimal in human prevention trials [54].
In this study, we generated a pool of 16 SHIVenv’s 
derived from the HIV-1 env genes of acute HIV-1 infec-
tions. The production of these SHIVenv’s was not a sim-
ple task and first required our development of an SIV and 
SHIV cloning system similar to the yeast-based cloning 
system for HIV-1 [20, 55, 56]. Del Prete et al. [16] used 
conventional cloning strategy to generate a cocktail 
of multiple of SHIVenv viruses. This method requires 
unique restriction enzyme sites which is usually difficult 
due to the extreme diversity of HIV sequences. In order 
to circumvent this difficulty, we utilized a yeast based 
recombination technology which only relies on sequence 
similarity and can insert a DNA fragment in one step 
within yeast without the need of restriction enzyme 
digestion, in vitro ligation and transformations. Through 
yeast recombination and gap repair, we shuttled over 70 
versions of HIV-1 env and gp120 coding regions from 20 
AHI’s into our SHIVKB9 vector and tested for virus pro-
duction, entry efficiency, and virus propagation. Replace-
ment of the HIV-1 KB9 with the entire env coding region 
in SHIVenv resulted in very low levels of virus produc-
tion. The env gene carries the second exon of tat/rev 
and generates a chimera of KB9/AHI Rev and Tat pro-
teins which appears incompatible for efficient transcrip-
tion and mRNA transport. To avoid the split in rev/tat 
exons, we introduced the 20 AHI env genes as cassettes 
that included the first exon of tat/rev into SIVmac239 but 
again virus production and Env expression was too low to 
warrant further study. Previous studies have shown that 
the “KB9 Env” in the SIVmac239 has adapted to replica-
tion in macaques due in part to mutations in the extra-
cellular domain of gp41 [57], i.e. a region that would be 
replaced by rev/tat-env cassette. In the end, cloning of 
the gp120 and partial gp41 (upstream to the second exon 
of rev/tat) from these AHI’s into SHIVKB9 preserved the 
KB9 Rev/Tat proteins and gp41 extracellular domain, 
and resulted in high level virus production from provi-
ral transfections. These viruses (termed SHIVenv_B1 to 
_B20 for simplicity) had the correct stoichiometry of SIV 
proteins and fully functional HIV-1 glycoproteins but 
were unable to maintain long-term replication in vari-
ous cell lines and primary, activated PBMCs of human or 
macaque origin.
SHIVenv_B viruses could support transient infection 
of different cell lines and primary macaque PBMCs but 
could not be propagated. Several groups have shown 
that propagation of SHIVenv in these primary cells 
or cell lines in not indicative of subsequent infection 
or pathogenesis in macaques [13, 30, 31]. In fact, the 
original SHIVenv_89.6 clone did not replicate in cul-
ture but could infect macaques and is the progenitor of 
the CXCR4-using SHIVenv_KB9 virus. These observa-
tions were the primary reason to proceed with a pooled 
SHIVenv_B exposure in macaques. Based on Env func-
tion, viral protein content, and transient replication, we 
selected 16 of 20 SHIVenv_B viruses for this pool. Infec-
tion was observed in one of two macaques but only one 
of 16 SHIV viruses (i.e. SHIVenv_B3) successfully estab-
lished infection. It is important to stress that the goal 
of this study was to establish prolonged macaque infec-
tion with SHIVenv derived from AHI and then passage 
through new macaques to enhance pathogenicity. We 
sequenced the entire SHIVenv_B genomes from each of 
the 16 clones and did not observe any mutations in the 
SHIVKB9 backbone prior to infection. Furthermore, the 
SHIVenv_B3 during infection of m328-08 only had sto-
chastic non-synonymous substitutions without dominant 
amino acid substitutions in the coding sequence across 
the entire proteome (including the env_B3). As reported 
in [19], SHIVenv_B3 did establish a long term pathogenic 
infection when passaged from m328-08 to m165-05 but 
this enhanced virulence was associated with discrete 
amino acid substitution in Env_B3 appearing only in the 
m165-05 animal. Finally, we confirmed that SHIVenv_B3 
alone could establish infection in three other macaques 
and did not require the presence of 15 other SHIVenv_B 
viruses in the pool.
Infection with only one of 16 SHIVenv_B clones could 
be due to a stochastic/random event or may be related 
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to distinct properties of SHIVenv_B3 compared to the 
other AHI env clones within the isogenic SHIVKB9 back-
bone. Since the SHIVenv_B viruses could not replicate 
long term in culture, we constructed the equivalent the 
HIVenv_B chimeric viruses derived from the same 16 
AHI env genes but within an NL4-3 backbone. Despite 
the different SIV and HIV-1 backbones, we observed a 
direct correlation between the relative levels of cell fusion 
mediated 16 Env_B glycoproteins in the HIV-1 ver-
sus SIV backbone. A previous study involving macaque 
infections with a pool of SHIVenv viruses indicated that 
the SHIVenv with highest replication efficiency estab-
lished infection in macaques [16]. In both SHIVenv 
monoinfections the macaque PBMCs and in competi-
tive fitness assays using human PBMCs and HIV-1env 
counterparts, the Env_B3 did not show enhanced repli-
cative efficiency. The most fit Env_B16 was not detected 
in the infected macaque and neither was 12 other AHI 
Env’s that had higher replicative fitness and/or entry effi-
ciency. The Env_B3 mediated fourth (of 16) highest level 
of host cell entry as determined by Veritrop. Cell fusion 
was with these 16 AHI Env_B glycoproteins as compared 
to cell fusion mediated with another set of 26 HIVenv 
chimeric viruses derived from AHI cohort at Aaron Dia-
mond/New York University [25], i.e. a pool of AHI that 
encompassed those SHIVenv employed by Del Prete et al. 
[16]. When analyzing free virus using the Affinofile sys-
tem [24, 25], we found that the HIVenv chimeric viruses 
from CHAVI AHI and from the NYU AHI showed a wide 
range of affinity, avidity, and usage of CD4 and CCR5 for 
host cell entry. HIV-1 with Env_B3 was more efficient 
than the majority at host cell entry at high CCR5 across 
of range of CD4 levels on the cell surface but was only 
average when scavenging for low levels of CCR5. When 
comparing the kinetics of host cell entry, the HIVenv_B3 
was slightly faster at these early steps of replication, rank-
ing 3rd of the 16 HIVenv_B3 strains. However, HIVenv_
B3 had lower than average replicative fitness when 
compared to the other 15 HIVenv_B viruses, all of which 
were competed against three control strains in human 
PBMCs. Our previous study with these HIVenv chimeric 
viruses also showed that HIVenv_B3 had no replicative 
advantage in primary macrophages, dendritic-T cell co-
cultures, or infection of vaginal tissue [37]. This array of 
phenotypic assays suggests that HIVenv_B3 is only aver-
age in terms of replicative fitness and host cell entry.
According to a recent study [17], residue at position 
375 is important in determining HIV-1 Env binding affin-
ity to macaque CD4, i.e. S375 Env had minimum binding 
affinity, while mutation of S375M, Y, H, W, and F could 
significantly enhance the RhCD4 binding affinity and 
subsequent viral replication in macaque primary CD4 
T cells. In our study, the 11 of 16 SHIV strains in the 
inoculating pool had an S375 which was associated with 
lower RhCD4 binding affinity. A375 and I375 were found 
in SHIVenv_B5 and _B12 While four strains had T375 
(B16, B17 and B18). None of these residues at 375 were 
associated with high RhCD4 affinity. An earlier study by 
Boyd et  al. [18] reported that independent introduction 
of the A204E and G312V mutations yielded functional 
HIV-1 Env glycoproteins on SIV capable of mediating 
cell infection via huCD4 and RhCD4 receptors. None of 
our 16 strains had either 204E or 312V. In our study, we 
did not deplete macaque CD8+ T cells or alter the acute/
early HIV-1 env genes cloned into the SHIVenv_KB9 
backbone. Our intention was to select for the HIV-1 env 
gene (derived from acute infections) with the highest 
transmission efficiency in rhesus macaques and provid-
ing the best native HIV-1 env for subsequent SHIVenv 
studies on macaque infection and pathogenesis. It is also 
possible that in vitro adaptation step might help to find 
an effective SHIVenv strain.
Asmal et al. [58] previously showed that there is a strong 
association between a positively charged amino acid like 
histidine at position 12 in transmitted/founder viruses 
with more efficient trafficking of the nascent envelope 
polypeptide to the endoplasmic reticulum and higher 
steady-state glycoprotein expression compared to viruses 
that have a non-basic position 12 residue, a substitution 
that was enriched among viruses sampled from chroni-
cally infected individuals. In the present study, the major-
ity of 16 AHI viruses derived Envs including B3 contain 
histidine or other positively charged amino acids (e.g. 
Arginine) at position 12, and only B8 and B18 have non-
basic amino acids at the same position. However, when 
comparing the Env sequences from these 16 AHIs, we 
did discover that the Env_B3 had the fewest conserved 
N-linked glycosylation sites in V1/V2 and V4/V5 loops 
and in env gene overall. The Env_B3 also had the least 
positively charged V3 loop (aside from B7) and the low-
est PSSM score, two measures predictive of relative CCR5 
versus CXCR4 usage. Increased high-mannose N-linked 
glycosylation accounts for 50% of the Env glycoprotein 
mass, can reduce the viral antigenicity and protect func-
tional regions of Env from host antibodies [59–64]. Pre-
vious studies have shown that HIV-1 derived from acute/
early infection typically have fewer N-linked glycosyla-
tion sites [65, 66]. We propose that based on the further 
reduction of conserved N-linked sites, the Env_B3 may 
have 30% less high mannose glycans than even other AHI 
Env’s and up to 40% less than the average Env glycopro-
tein found during chronic disease. The role of Env glyco-
sylation on HIV-1 transmission still remains unclear. Early 
reports suggested that high transmission efficiency of 
HIV-1 with reduced glycosylation was related to a com-
pact Env glycoprotein where interactions with CD4/CCR5 
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and subsequent confirmation changes was not impeded by 
the bulk high mannose glycans. Since anti-Env antibodies 
do not appear for 2–3 weeks post infection, there would be 
no selection to maintain the highly glycosylated Env on the 
transmitted HIV-1 strains. However, we have no evidence 
to suggest an increased receptor binding, host cell entry, 
or replicative fitness of HIV-1 with fewer N-linked sites in 
Env. In contrast, the Env glycoproteins from chronic dis-
ease and with more N-linked sites typically have higher 
replicative fitness [25]. Some SIV transmission studies 
showed that activated CD4 cells but not DCs are the ini-
tial targets of infection [67–69]. It has been reported that 
reduced glycosylation of Env may enhance binding to α4β7 
integrin found on gut CD4+ T cells, which may then be 
associated with rapid depletion of this Th17 T cells in 
the gut during early HIV-1 infection [70]. On the other 
hand, glycans have been implicated in viral transmission 
through interaction with lectins, in particular the C-type 
lectin DC-SIGN, which is found on dendritic cells (DCs) 
and specific macrophages, and is thought to aid the trans-
port of virus to anatomical sites rich in CD4+ T cells, such 
as lymph nodes [71, 72]. The observation of transmitted 
HIV with fewer N-linked sites has always run counter to 
the role of DC sign in transmission. In addition, binding 
of HIV-1 to C-type lectin Langerin, found on the surface 
of Langerhans’ cells is now associated with endocytosis 
and degradation of HIV-1 [71]. Langerhans’ cells are the 
primary DCs found in mucosal tissue. Regardless of these 
mechanisms, it is important to stress that selective trans-
mission of the SHIVenv_B3, with the fewest N-linked sites, 
followed intravenous injection and not through exposure 
through a mucosal route. Thus, we can only speculate the 
role of various mechanisms on the selection of SHIVenv 
with the least glycosylated Env.
Conclusions
We utilized the env gene from 20 acute HIV-1 infections to 
construct over 70 SHIVenv viruses using our yeast based 
cloning system. Based on reiterative cloning of various 
cassettes, we discovered that the selective introduction 
of a gp120 coding region into a SHIVenv_KB9 construct 
resulted in virus production with a functional Env. Despite 
the inability to propagate in primary cells and cell lines, a 
pool of 16 SHIVenv viruses could establish infection but 
only one virus, SHIVenv_B3 was isolated in the macaque 
and then shown to repeatedly infected macaques. This 
SHIVenv_B3 virus did not show any distinct phenotypic 
property from the other 15 SHIVenv viruses but did have 
the fewest N-linked glycosylation sites. As described in 
the companion article, the SHIVenv_B3 from the m328-08 
animal was passaged to the m165-05 where it established 
a prolonged and pathogenic infection associated with 
distinct amino acid changes in the Env glycoprotein. We 
propose that the env genes from AHI have already under-
gone a selection for efficient transmission in human hosts. 
The SHIVenv_B3 may be the best of these AHI Envs for 
transmission in macaques and may provide the virus tem-
plate to achieve both efficient infection and evolution to 
pathogenic CCR5-using SHIV.
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